JYJian Yu

Jian Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jian Yu has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Wei-Ping Zhou

    The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China

    3 shared publications
  • Chun-Fang Gao

    Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    2 shared publications
  • Qin Qi

    Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    2 shared publications
  • Qingguo Xu

    Organ Transplantation Center, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China; Academician Workstation, Changsha Medical University, Changsha, 410219, China

    2 shared publications
  • Rui Zhong

    Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    2 shared publications
  • Shengxian Yuan

    The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China

    2 shared publications

Latest Publications

  • Open Access

    Hepatitis B virus pregenomic RNA is associated with malignant phenotypes and postoperative survival in HBV-related intrahepatic cholangiocarcinoma

    by Qiyu Tian, Wen Li, Pengpeng Li, Yuanyuan Wang, Judian Yu, Jian Yu, Gang Huang

    Background: Chronic hepatitis B virus (HBV) infection contributes to infection-associated liver carcinogenesis. However, the biological and clinical relevance of HBV pregenomic RNA (pgRNA), a marker of residual viral transcriptional activity, in HBV-related intrahepatic cholangiocarcinoma (iCCA) remains insufficiently defined. Methods: This single-center retrospective exploratory translational study included 45 patients with HBV-related iCCA who underwent curative resection after long-term nucleos(t)ide analogue therapy and had suppressed preoperative serum HBV DNA. Tissue pgRNA expression was measured by quantitative reverse-transcription polymerase chain reaction (qRT-PCR), serum pgRNA was quantified by simultaneous amplification and testing (SAT), and spatial localization was assessed by immunofluorescence–fluorescence in situ hybridization (IF-FISH). Stable pgRNA-overexpressing HuCCT1 and RBE models were used to evaluate cell viability, migration, invasion, colony formation and stemness-related protein expression. Associations between serum pgRNA status and postoperative outcomes were examined using Kaplan–Meier, Cox regression and restricted mean survival time analyses. Results: Tumor tissues showed lower overall pgRNA expression than paired adjacent non-tumor liver tissues, whereas pgRNA signals were detectable in a subset of CK19-positive tumor epithelial cells. In HuCCT1 and RBE cells, pgRNA overexpression was associated with increased cell viability, migration, invasion, colony formation and upregulation of multiple stemness-related proteins. In the clinical analysis, the serum pgRNA HIGH group had poorer overall survival (adjusted HR = 5.22, 95% CI 1.82–14.95; P = 0.002) and recurrence-free survival (adjusted HR = 3.51, 95% CI 1.26–9.79; P = 0.017) than the BLQ group after adjustment for tumor size. Conclusions: HBV pgRNA may be linked to malignant and stemness-related phenotypes in HBV-related iCCA. High preoperative serum pgRNA was associated with poorer postoperative overall and recurrence-free survival in this exploratory cohort. These findings support validation of pgRNA as a candidate infection-related biomarker in larger prospective multicenter studies.

  • Open Access

    FTSJ1-mediated IL1RN mRNA instability promotes inflammation-driven hepatocellular carcinoma

    by Shuya Jiang, Dongyang Ding, Yunxi Zu, Yan Liao, Tengjiao Wang, Jian Yu, Weiping Zhou, Shengxian Yuan

    Background: The role of 2'-O-methyltransferases in hepatocellular carcinoma (HCC) progression, particularly concerning inflammation, remains unclear. This study investigated their prognostic significance, identified key prognostic target FTSJ1, and elucidated its inflammatory-related biological functions and molecular mechanisms. Methods: Transcriptomic data from The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA-LIHC) were integrated to data of subtype HCC patients via consensus clustering based on 2'-O-methyltransferase expression. Single-gene survival analysis linked FTSJ1, FTSJ2, FTSJ3, and FBL to prognosis. A four-gene risk model was built. Multivariate COX regression identified independent risk factors. FTSJ1 expression and prognostic value were validated clinically using quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). Functional roles were assessed in vitro [Cell Counting Kit-8 (CCK-8), Transwell, apoptosis/cell cycle assays] and in vivo (xenograft models). Mechanisms were explored via RNA sequencing (RNA-seq), gene set enrichment analysis (GSEA), and inflammatory cytokine detection. Results: Consensus clustering defined three subtypes. Subtype 1 (high 2'-O-methyltransferase expression) showed the worst prognosis. FTSJ1/2/3 and FBL correlated significantly with survival. The four-gene risk model predicted survival across cohorts [The Cancer Genome Atlas (TCGA)/Gene Expression Omnibus (GEO) datasets (GSE54236/GSE144269)]. FTSJ1 was an independent risk factor [multivariate Cox, hazard ratio (HR) =2.268, P=0.01] and significantly elevated in HCC tissues. Functionally, FTSJ1 knockdown inhibited proliferation and migration; induced G0/G1 arrest; promoted apoptosis in vitro; and suppressed tumor growth in vivo. Mechanistically, FTSJ1 drove HCC progression by reducing RNA stability of the key anti-inflammatory gene interleukin 1 receptor antagonist (IL1RN), leading to downregulated tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) and enhanced pro-inflammatory signaling. Conclusions: High 2'-O-methyltransferase abundance predicts poor HCC prognosis. FTSJ1 is a novel independent prognostic biomarker and oncogenic factor that promotes HCC progression by dysregulating the inflammatory response pathway, highlighting its translational potential in inflammation-driven HCC.


  • Top Cited Papers
    Open Access

    The RNA M5C methyltransferase NSUN2 promotes progression of hepatocellular carcinoma by enhancing PKM2-mediated glycolysis

    by Qin Qi, Rui Zhong, Yan Huang, Yong Tang, Xiao-Wen Zhang, Chang Liu, Chun-Fang Gao, Lin Zhou, Jian Yu, Lu-Yi Wu

    Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The 5-methylcytosine (m5C) RNA methyltransferase NSUN2 is involved in cell proliferation and metastasis and is upregulated in a variety of cancers. However, the biological function and regulatory mechanism of NSUN2-mediated m5C modification have not been well studied in HCC. Our results showed that NSUN2 is upregulated and associated with poor prognosis in HCC patients after hepatectomy. NSUN2 overexpression significantly promoted HCC growth and metastasis, whereas NSUN2 knockdown had the opposite effect. m5C RNA immunoprecipitation sequencing (m5C-RIP-Seq) revealed that m5C hypermethylation correlates with mRNA overexpression and that NSUN2-mediated m5C hypermethylation promotes metabolism in HCC patients. Mechanistically, our data revealed that PKM2, a terminal enzyme in the glycolytic pathway, is a downstream target of NSUN2-mediated m5C modification. Specifically, NSUN2 could stabilize PKM2 mRNA by increasing the m5C level of the m5C site C773 in the 3′-UTR of PKM2 mRNA. In addition, rescue assays revealed that NSUN2 promotes HCC glycolysis and progression by upregulating PKM2. In conclusion, this study revealed that NSUN2-mediated m5C modification promotes glycolysis and the progression of hepatocellular carcinoma by stabilizing PKM2 mRNA, and provides a potential prognostic factor and therapeutic target for HCC patients.


  • Open Access

    NSUN5 promotes progression and predicts poor prognosis in hepatocellular carcinoma

    by Xiao-Wen Zhang, Lu-Yi Wu, Hui-Rong Liu, Yan Huang, Qin Qi, Rui Zhong, Lu Zhu, Chun-Fang Gao, Lin Zhou, Jian Yu, et al.

    The 5‑methylcytosine (m5C) RNA methyltransferase NOP2/Sun RNA methyltransferase 5 (NSUN5) has been reported to serve important roles in numerous diseases. However, the functions and clinical significance of NSUN5 in hepatocellular carcinoma (HCC) remain unknown. Clinical information and NSUN5 mRNA sequencing data for 374 patients with HCC were downloaded from The Cancer Genome Atlas (TCGA) database, and NSUN5 mRNA and protein expression levels in 120 patients with HCC (present study cohorts) were assessed using reverse transcription‑quantitative PCR, western blotting or immunohistochemistry. The association between NSUN5 mRNA and protein expression levels and the clinical characteristics (or prognosis) of patients with HCC was analyzed using the χ2 or log‑rank test. The functions of NSUN5 in HCC were evaluated using in vitro and in vivo experiments, and the mechanism by which NSUN5 affected the progression of HCC was assessed using bioinformatics analysis using LinkedOmics. NSUN5 was significantly upregulated and predicted poor prognosis in HCC according to data from both TCGA database and present study cohorts. NSUN5 significantly promoted HCC proliferation and migration in vitro and significantly induced HCC tumor growth in vivo. Bioinformatics analysis demonstrated that NSUN5 was positively correlated with genes associated with translation in HCC. It was hypothesized that overexpression of NSUN5 strengthened ribosome functions and global protein translation, which may promote the proliferation and migration of HCC. In conclusion, NSUN5 may promote the progression of HCC by enhancing translation, thus making it a potential target for HCC treatment.


  • Open Access

    Plasma Circular RNA Panel to Diagnose Hepatitis B Virus-Related Hepatocellular Carcinoma

    by Jian Yu, Meng-Chao Wang, Wen-Bing Ding, Xing-Gang Guo, Jian Xu, Qing-Guo Xu, Yuan Yang, Shu-Han Sun, Jing-Feng Liu, Lun-Xiu Qin, et al.

    To explore whether plasma circular RNAs (circRNAs) can diagnose hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), microarray and qPCR were used to identify plasma circRNAs that were increased in HCC patients compared with controls (including healthy controls, chronic hepatitis B, HBV-related liver cirrhosis and HCC patients). A logistic regression model was constructed using a training set (n=313) and then validated using another two independent sets (n=306 and 526, respectively). Area under the receiver operating characteristic curve (AUC) was used to evaluate diagnostic accuracy. We identified a plasma circRNA panel (CircPanel) containing three circRNAs (hsa_circ_0000976, hsa_circ_0007750 and hsa_circ_0139897) that could detect HCC. CircPanel showed a higher accuracy than AFP (alpha-fetoprotein) to distinguish individuals with HCC from controls in all three sets (AUC 0.863 [95% CI 0.819–0.907] vs 0.790 [0.738–0.842], P=0.036 in training set; 0.843 [0.796–0.890] vs 0.747 [0.691–0.804], P=0.011 in validation set 1 and 0.864 [0.830–0.898] vs 0.769 [0.728–0.810], PWhat is already known about this subject? The diagnostic accuracy of alpha-fetoprotein (AFP) in detecting hepatocellular carcinoma (HCC) is unsatisfactory. Circular RNA (circRNA) expression profiles in HCC and adjacent nontumor liver tissues are significantly different. Plasma circRNAs are enriched, stable and can be biomarkers for various diseases. What are the new findings? The expression of circRNAs in the plasma from HCC patients and chronic hepatitis B is significantly different. Plasma circRNA panel (CircPanel, including hsa_circ_0000976, hsa_circ_0007750 and hsa_circ_0139897) has a higher accuracy than AFP to distinguish individuals with HCC or Small-HCC (solitary, ≤3cm) from controls (healthy controls, chronic hepatitis B and HBV-related liver cirrhosis). CircPanel also performs well in diagnosing AFP-negative HCC and AFP-negative Small-HCC. How might it impact on clinical practice in the foreseeable future? Plasma CircPanel can be a diagnostic biomarker in detecting HCC and improves the diagnostic accuracy.

  • Open Access

    Aldolase B inhibits metastasis through Ten–Eleven Translocation 1 and serves as a prognostic biomarker in hepatocellular carcinoma

    by Qi-Fei Tao, Sheng-Xian Yuan, Fu Yang, Sen Yang, Yuan Yang, Ji-Hang Yuan, Zhen-Guang Wang, Qing-Guo Xu, Kong-Ying Lin, Jie Cai, et al.

    Downregulation of Aldolase B (ALDOB) has been reported in hepatocellular carcinoma. However, its clinical significance and its role in pathogenesis of HCC remain largely unknown. We analyzed the expression of ALDOB and its clinical features in a large cohort of 313 HCC patients using tissue microarray and immunohistochemistry. Moreover, the function of stably overexpressed ALDOB in HCC cells was explored in vitro and in vivo. Gene expression microarray analysis was performed on ALDOB-overexpressing SMMC7721 cells to elucidate its mechanism of action. ALDOB downregulation in HCC was significantly correlated with aggressive characteristics including absence of encapsulation, increased tumor size (>5 cm) and early recurrence. ALDOB downregulation was indicative of a shorter recurrence-free survival (RFS) and overall survival (OS) for all HCC patients and early-stage HCC patients (BCLC 0-A and TNM I stage patients). Multiple analyses revealed that ALDOB downregulation was an independent risk factor of RFS and OS. Stable expression of ALDOB in HCC cell lines reduced cell migration in vitro and inhibited lung metastasis, intrahepatic metastasis, and reduced circulating tumor cells in vivo. Mechanistically, we found that cells stably expressing ALDOB show elevated Ten–Eleven Translocation 1 (TET1) expression. Moreover, ALDOB expressing cells have higher levels of methylglyoxal than do control cells, which can upregulate TET1 expression. The downregulation of ALDOB could indicate a poor prognosis for HCC patients, and therefore, ALDOB might be considered a prognostic biomarker for HCC, especially at the early stage. In addition, ALDOB inhibits the invasive features of cell lines partly through TET1 expression.